* Significant differences (p < 0.05) were found between polycystic ovary syndrome (PCOS) groups and healthy controls for all biochemical markers.
Declarations
Acknowledgments
The authors would like to express their gratitude to the staff of the Infertility and IVF Center at Yarmouk Teaching Hospital, Baghdad, for their support during the data collection phase. We also thank all the participants who volunteered for this study.
Author contributions
SOY: Conceptualization, Methodology, Supervision, Visualization. MDA: Conceptualization, Methodology, Supervision. SMA: Investigation, Data curation. IKD: Investigation, Data curation. SM: Formal analysis, Writing—original draft, Writing—review & editing. JS: Formal analysis. All authors read and approved the submitted version.
Conflicts of interest
The authors declare that they have no conflicts of interest.
Ethical approval
The study was reviewed and approved by the Middle Technical University Medical Ethics Committee in Baghdad, Iraq (Ethics Reference Number: 37, approved on October 27, 2025). All procedures were conducted in strict adherence to the WMA Declaration of Helsinki.
Consent to participate
Informed consent was obtained from all adult participants prior to their inclusion in the study.
Consent to publication
Not applicable.
Availability of data and materials
The datasets generated and analyzed during the current study are available from the corresponding author upon reasonable request.
Funding
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.
References
Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, et al. Polycystic ovary syndrome.Nat Rev Dis Primers. 2016;2:16057. [DOI] [PubMed]
Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome.Fertil Steril. 2016;106:6–15. [DOI] [PubMed]
Raja MHR, Javed MA, Rehman R. Pathophysiology of polycystic ovary syndrome. In: Rehman R, Sheikh A, editors. Polycystic Ovary Syndrome. 1st ed. Amsterdam: Elsevier; 2024. pp. 23–32. [DOI]
Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.Endocr Rev. 2012;33:981–1030. [DOI] [PubMed] [PMC]
Abbas MD, Egbe SS. The seroprevalence of CMV in women with bad obstetric history in Babil/Iraq.Iraqi J Pharm Sci. 2021;30:1–7.
Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection.Rev Med Virol. 2010;20:202–13. [DOI] [PubMed]
Ji YN, An L, Zhan P, Chen XH. Cytomegalovirus infection and coronary heart disease risk: a meta-analysis.Mol Biol Rep. 2012;39:6537–46. [DOI] [PubMed]
Hadi Khorsheed ZM, Al-shibly IKA, Gatea AK. Relationship Between Human Cytomegalovirus and IL-17A in Iraqi Women with Polycystic Ovary Syndrome.Al-Rafidain J Med Sci. 2024;6:178–81. [DOI]
Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences.Behav Res Methods. 2007;39:175–91. [DOI] [PubMed]
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.Fertil Steril. 2004;81:19–25. [DOI] [PubMed]
Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Martikainen HK, Tapanainen JS. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.J Clin Endocrinol Metab. 2000;85:3161–8. [DOI] [PubMed]
Miller-Kittrell M, Sparer TE. Feeling manipulated: cytomegalovirus immune manipulation.Virol J. 2009;6:4. [DOI] [PubMed] [PMC]
Kayesh MEH, Kohara M, Tsukiyama-Kohara K. Effects of oxidative stress on viral infections: an overview.Npj Viruses. 2025;3:27. [DOI] [PubMed] [PMC]
La Rosa C, Diamond DJ. The immune response to human CMV.Future Virol. 2012;7:279–93. [DOI] [PubMed] [PMC]
Talbott E, Guzick D, Clerici A, Berga S, Detre K, Weimer K, et al. Coronary heart disease risk factors in women with polycystic ovary syndrome.Arterioscler Thromb Vasc Biol. 1995;15:821–6. [DOI] [PubMed]
